Sugi Predict

Sugi Predict / Compounds / SCHEMBL8239668

SCHEMBL8239668

SCHEMBL8239668

C=C(C)CC1CCCCC1=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 5/20 0.42
▸ CA2 P00918 5/20 0.42
▸ CA4 P22748 5/20 0.42
▸ CA6 P23280 4/20 0.42
▸ NPC1 O15118 3/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ GAA P10253 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ PTGS1 P23219 5/20 0.38
▸ PTGS2 P35354 5/20 0.38
▸ HTT P42858 2/20 0.38
▸ OPRK1 P41145 1/20 0.38
▸ LMNA P02545 1/20 0.36
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14343841 0.98 CA1 (0.45) CA1CA2CA4CA6NPC1
SCHEMBL1278415 0.98 CA1 (0.45) CA1CA2CA4CA6NPC1
SCHEMBL9079832 0.94 NPC1 (0.41) CA1CA2CA4CA6NPC1
SCHEMBL1188324 0.82 NPC1 (0.46) CA1CA2CA4CA6NPC1
SCHEMBL11796309 0.81 NPC1 (0.54) CA1CA2CA4CA6NPC1
SCHEMBL1981599 0.81 CA1 (0.46) CA1CA2CA4CA6NPC1
SCHEMBL28365490 0.81 CA1 (0.46) CA1CA2CA4CA6NPC1
SCHEMBL1978465 0.81 CA1 (0.46) CA1CA2CA4CA6NPC1
SCHEMBL14462105 0.80 NPC1 (0.52) CA1CA2CA4CA6NPC1
SCHEMBL14478516 0.79 CA1 (0.45) CA1CA2CA4CA6NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116807912-A Use of volatile components to limit or eliminate perception of malodor 弗门尼舍有限公司 2023-09-29 — — CN claimed
CN-111432851-A Use of volatile ingredients to limit or eliminate perception of malodour 弗门尼舍有限公司 2020-07-17 — — CN claimed
CN-111295204-A Spiro compounds as malodor counteracting ingredients 弗门尼舍有限公司 2020-06-16 — — CN claimed
CN-116807912-A Use of volatile components to limit or eliminate perception of malodor 弗门尼舍有限公司 2023-09-29 — — CN disclosed
CN-116763963-A Spiro compounds as malodor counteracting ingredients 弗门尼舍有限公司 2023-09-19 — — CN disclosed
US-11685705-B2 Method for producing α-allylated cycloalkanone KAO CORPORATION (JP) 2023-06-27 — — US disclosed
CN-111432851-B Use of volatile components to limit or eliminate perception of malodor 弗门尼舍有限公司 2023-06-23 — — CN disclosed
US-11524929-B2 Method for producing alpha-allylated cycloalkanone KAO CORPORATION (JP) 2022-12-13 — — US disclosed
US-20220153671-A1 METHOD FOR PRODUCING ALPHA-ALLYLATED CYCLOALKANONE KAO CORPORATION (JP) 2022-05-19 — — US disclosed
CN-109641814-B Non-corrosive nitration inhibitor polar solvent preparation 美国陶氏益农公司 2021-12-31 — — CN disclosed
WO-2020189670-A1 METHOD FOR PRODUCING α – ALLYLATED CYCLOALKANONE 花王株式会社 2020-09-24 — — WO disclosed
US-8203004-B2 Tetrahydroindole derivatives for treatment of alzheimer's disease MERCK, SHARP & DOHME LIMITED (GB) 2012-06-19 — — US disclosed
US-8203004-B2 Tetrahydroindole derivatives for treatment of alzheimer's disease MERCK, SHARP & DOHME LIMITED (GB) 2012-06-19 — — US disclosed
US-20100016308-A1 Tetrahydroindole Derivatives for Treatment of Alzheimer's Disease MERCK SHARP & DOHME LIMITED (GB) 2010-01-21 — — US disclosed
US-20100016308-A1 Tetrahydroindole Derivatives for Treatment of Alzheimer's Disease MERCK SHARP & DOHME LIMITED (GB) 2010-01-21 — — US disclosed
WO-2007054739-A1 TETRAHYDROINDOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2007-05-18 — — WO disclosed
EP-0381964-B1 PROCESS FOR THE PREPARATION OF POLYUNSATURATED CYCLIC COMPOUNDS FIRMENICH SA (CH) 1993-03-17 — — EP disclosed
US-4967033-A Process for the preparation of polyunsaturated cyclic compounds FIRMENICH S.A. (CH) 1990-10-30 — — US disclosed
EP-0381964-A1 Process for the preparation of polyunsaturated cyclic compounds FIRMENICH SA (CH) 1990-08-16 — — EP disclosed
US-4362670-A Allylation of carbon compounds THE DOW CHEMICAL COMPANY (US) 1982-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524929-B2 Method for producing alpha-allylated cycloalkanone ADH1A, ADH1C, ADH5 CA1 600/4885CA2 2184/4885CA4 1865/4885
US-20220153671-A1 METHOD FOR PRODUCING ALPHA-ALLYLATED CYCLOALKANONE ADH1A, ADH1C, ADH5 CA1 600/4885CA2 2184/4885CA4 1865/4885
US-20100016308-A1 Tetrahydroindole Derivatives for Treatment of Alzheimer's Disease BACE1, BACE2, PSEN2 CA1 916/4885CA2 4099/4885CA4 4427/4885
US-11685705-B2 Method for producing α-allylated cycloalkanone AKR1C3, GALK1, PYM1 CA1 2387/4885CA2 2857/4885CA4 1407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.